Applied DNA Sciences Inc (APDN) - Net Assets
Based on the latest financial reports, Applied DNA Sciences Inc (APDN) has net assets worth $6.99 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.93 Million) and total liabilities ($2.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check APDN financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.99 Million |
| % of Total Assets | 70.34% |
| Annual Growth Rate | N/A |
| 5-Year Change | -82.53% |
| 10-Year Change | -81.27% |
| Growth Volatility | 186.22 |
Applied DNA Sciences Inc - Net Assets Trend (2001–2025)
This chart illustrates how Applied DNA Sciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore APDN total asset value for the complete picture of this company's asset base.
Annual Net Assets for Applied DNA Sciences Inc (2001–2025)
The table below shows the annual net assets of Applied DNA Sciences Inc from 2001 to 2025. For live valuation and market cap data, see Applied DNA Sciences Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $1.94 Million | -78.35% |
| 2024-09-30 | $8.97 Million | +84.06% |
| 2023-09-30 | $4.87 Million | -62.26% |
| 2022-09-30 | $12.91 Million | +16.16% |
| 2021-09-30 | $11.11 Million | +94.64% |
| 2020-09-30 | $5.71 Million | +772.89% |
| 2019-09-30 | $-848.50K | -212.46% |
| 2018-09-30 | $754.50K | -89.00% |
| 2017-09-30 | $6.86 Million | -33.84% |
| 2016-09-30 | $10.37 Million | -17.52% |
| 2015-09-30 | $12.57 Million | +955.78% |
| 2014-09-30 | $-1.47 Million | -131.81% |
| 2013-09-30 | $4.62 Million | +509.84% |
| 2012-09-30 | $756.92K | +176.04% |
| 2011-09-30 | $-995.38K | +37.71% |
| 2010-09-30 | $-1.60 Million | +8.52% |
| 2009-09-30 | $-1.75 Million | +87.56% |
| 2008-09-30 | $-14.04 Million | -17.52% |
| 2007-09-30 | $-11.94 Million | -24.60% |
| 2006-09-30 | $-9.59 Million | -245.54% |
| 2005-09-30 | $6.59 Million | +239.95% |
| 2004-09-30 | $-4.71 Million | -715.08% |
| 2003-09-30 | $-577.43K | -69637.56% |
| 2001-09-30 | $-828.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Applied DNA Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37835850100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.66K | 0.09% |
| Other Components | $381.10 Million | 19627.22% |
| Total Equity | $1.94 Million | 100.00% |
Applied DNA Sciences Inc Competitors by Market Cap
The table below lists competitors of Applied DNA Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Autonomix Medical, Inc. Common Stock
NASDAQ:AMIX
|
$3.99 Million |
|
Ximen Mining Corp
V:XIM
|
$3.99 Million |
|
Stellar AfricaGold Inc.
V:SPX
|
$3.99 Million |
|
CT UK Capital And Income Investment Trust Plc
LSE:CTUK
|
$4.01 Million |
|
M3 Mining Ltd
AU:M3M
|
$3.99 Million |
|
Australian Silica Quartz Group Ltd
AU:ASQ
|
$3.99 Million |
|
Prima Alloy Steel Universal
JK:PRAS
|
$3.98 Million |
|
SILVER HAMMER MINING CORP
F:7BW0
|
$3.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Applied DNA Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,142,617 to 1,941,693, a change of -7,200,924 (-78.8%).
- Net loss of 69,487,620 reduced equity.
- Dividend payments of 54,326,896 reduced retained earnings.
- Other factors increased equity by 116,613,592.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-69.49 Million | -3578.71% |
| Dividends Paid | $54.33 Million | -2797.91% |
| Other Changes | $116.61 Million | +6005.77% |
| Total Change | $- | -78.76% |
Book Value vs Market Value Analysis
This analysis compares Applied DNA Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.82x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-09-30 | $-60.82 | $3.09 | x |
| 1998-09-30 | $-87.18 | $3.09 | x |
| 1999-09-30 | $-16.05 | $3.09 | x |
| 2001-09-30 | $0.03 | $3.09 | x |
| 2003-09-30 | $-106.97 | $3.09 | x |
| 2004-09-30 | $-542.54 | $3.09 | x |
| 2005-09-30 | $247.32 | $3.09 | x |
| 2006-09-30 | $-126.61 | $3.09 | x |
| 2007-09-30 | $-211.99 | $3.09 | x |
| 2008-09-30 | $-175.94 | $3.09 | x |
| 2009-09-30 | $-13.57 | $3.09 | x |
| 2010-09-30 | $-12.77 | $3.09 | x |
| 2011-09-30 | $-6.34 | $3.09 | x |
| 2012-09-30 | $3.16 | $3.09 | x |
| 2013-09-30 | $314.79 | $3.09 | x |
| 2014-09-30 | $-86.92 | $3.09 | x |
| 2015-09-30 | $530.85 | $3.09 | x |
| 2016-09-30 | $349.99 | $3.09 | x |
| 2017-09-30 | $207.98 | $3.09 | x |
| 2018-09-30 | $20.46 | $3.09 | x |
| 2019-09-30 | $-18.26 | $3.09 | x |
| 2020-09-30 | $29.18 | $3.09 | x |
| 2021-09-30 | $32.13 | $3.09 | x |
| 2022-09-30 | $28.80 | $3.09 | x |
| 2023-09-30 | $7.57 | $3.09 | x |
| 2024-09-30 | $2.31 | $3.09 | x |
| 2025-09-30 | $3.75 | $3.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Applied DNA Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3578.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3251.74%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 2.29x
- Recent ROE (-3578.71%) is below the historical average (-401.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 0.00% | 0.00% | 0.00x | 0.00x | $-269.10 |
| 1998 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.06K |
| 1999 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.26K |
| 2001 | -2484.44% | 0.00% | 0.00x | 1.00x | $-3.37K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.39 Million |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.89 Million |
| 2005 | -798.75% | 0.00% | 0.00x | 1.39x | $-53.27 Million |
| 2006 | 0.00% | -12752.58% | 0.00x | 0.00x | $-1.45 Million |
| 2007 | 0.00% | -10912.76% | 0.05x | 0.00x | $-12.11 Million |
| 2008 | 0.00% | -779.25% | 0.47x | 0.00x | $-5.40 Million |
| 2009 | 0.00% | 1336.41% | 0.20x | 0.00x | $4.12 Million |
| 2010 | 0.00% | -1521.53% | 0.37x | 0.00x | $-7.75 Million |
| 2011 | 0.00% | -1085.32% | 0.28x | 0.00x | $-10.42 Million |
| 2012 | -944.71% | -385.55% | 1.37x | 1.78x | $-7.23 Million |
| 2013 | -383.15% | -868.59% | 0.24x | 1.81x | $-18.15 Million |
| 2014 | 0.00% | -480.18% | 0.78x | 0.00x | $-12.92 Million |
| 2015 | -94.54% | -131.89% | 0.58x | 1.24x | $-13.14 Million |
| 2016 | -117.47% | -290.84% | 0.27x | 1.50x | $-13.21 Million |
| 2017 | -187.45% | -270.58% | 0.58x | 1.19x | $-13.54 Million |
| 2018 | -1549.75% | -299.56% | 0.69x | 7.47x | $-11.77 Million |
| 2019 | 0.00% | -160.18% | 1.51x | 0.00x | $-8.55 Million |
| 2020 | -223.23% | -660.89% | 0.17x | 1.98x | $-13.34 Million |
| 2021 | -144.23% | -177.56% | 0.63x | 1.30x | $-17.14 Million |
| 2022 | -64.89% | -46.11% | 0.82x | 1.72x | $-9.67 Million |
| 2023 | -200.90% | -74.41% | 0.98x | 2.76x | $-10.44 Million |
| 2024 | -76.48% | -203.78% | 0.27x | 1.40x | $-7.91 Million |
| 2025 | -3578.71% | -3251.74% | 0.48x | 2.29x | $-69.68 Million |
Industry Comparison
This section compares Applied DNA Sciences Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,209,926,476
- Average return on equity (ROE) among peers: -29.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Applied DNA Sciences Inc (APDN) | $6.99 Million | 0.00% | 0.42x | $3.99 Million |
| Agilent Technologies Inc (A) | $5.84 Billion | 21.21% | 0.84x | $32.49 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $6.75 Million |
| Biodesix Inc (BDSX) | $19.73 Million | -218.78% | 2.86x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $7.29 Million |
| Biocept Inc. (BIOCQ) | $37.48 Million | -7.53% | 0.61x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $480.11 Million | 1.55% | 0.32x | $3.57 Billion |
| Burning Rock Biotech Ltd (BNR) | $580.83 Million | -59.68% | 0.52x | $143.84 Million |
| CareDx Inc (CDNA) | $465.88 Million | -6.58% | 0.22x | $1.00 Billion |
| Check Cap Ltd (CHEK) | $-1.45 Million | 0.00% | 0.00x | $9.42 Million |
About Applied DNA Sciences Inc
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops… Read more